HC Wainwright Reaffirms "Buy" Rating for Roivant Sciences (NASDAQ:ROIV)
Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.53% from the company’s previous close. Other research analysts […]